Expression of hypoxia‐inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors
Authors:
Open Access
- 12 June 2020
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 10 (8) , e01718
Abstract
Background: It has been indicated that abnormal glucose metabolism mediated by hypoxia‐inducible factor 1α (HIF‐1α) played an essential role in the development of solid tumor. However, there were rare studies about the role of them in primary central nervous system lymphoma (PCNSL).Objective: To investigate the protein levels of HIF‐1α, glucose transporter 1 (GLUT1), and hexokinase 2 (HK2) in PCNSL and whether their levels are associated with prognostic factors.Methods: Expression of HIF‐1α, GLUT1, and HK2 in 39 tumor tissues was evaluated by immunohistochemical stainning. The correlation of the expression of HIF‐1α with the protein level of GLUT1 and HK2 was investigated. In addition, the association between these protein expression levels and clinical parameters and prognosis was analyzed.Results: In the tumor specimens of PCNSL, positive stainings of HIF‐1α, GLUT1, and HK2 were in 23 patients (58.97%), 25 patients (64.1%), and 26 patients (66.67%), respectively, which were associated with the expression level of lactic dehydrogenase (LDH), but not with age, gender, number of lesion, ECOG score, or deep structure. The expression of HIF‐1α was positively correlated with the expression of GLUT1 (p < .01, r = .749) and HK2 (p < .01, r = .787). Univariate analysis showed that upregulated GLUT1 was unfavorable predictors of progression‐free survival (PFS) in PCNSL. The results of Cox proportional hazards model showed GLUT1 was significantly associated with shorter PFS (hazard ration: 5.65; 95% confidence interval: 1.23–25.84; p = .026).Conclusions: This study indicated that there was a hypoxic microenvironment and HIF‐1α was involved in the regulation of glycolysis pathway in PCNSL. GLUT1 might be a potential marker for shorter PFS in PCNSL.Keywords
Funding Information
- National Natural Science Foundation of China (81272842)
- Natural Science Foundation of Beijing Municipality (7172071)
This publication has 34 references indexed in Scilit:
- Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of CancerCancer Cell, 2013
- Targeting glucose metabolism for cancer therapyJournal of Experimental Medicine, 2012
- Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell ProliferationAnnual Review of Cell and Developmental Biology, 2011
- Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioningBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic InhibitionJournal of Biological Chemistry, 2010
- RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularizationProceedings of the National Academy of Sciences, 2009
- Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomasNuclear Medicine and Biology, 2009
- Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesisSeminars in Cancer Biology, 2009
- Dysregulation of the TSC-mTOR pathway in human diseaseNature Genetics, 2004